Targeting sirtuin 1/nuclear factor erythroid 2-related factor 2/tumor necrosis factor-α pathway to modulate hepatic ischemia reperfusion-induced injury

Table 3 Effect of different doses of aprepitant on hepatic oxidative stress parameters in hepatic ischemia reperfusion-induced liver injury in rats

Group1	Hepatic MDA (nmol/g/protein)	Hepatic TAC (mM/g/protein)
Sham	2.444 ± 0.056	1.59 ± 0.008
Sham/APRE10	2.454 ± 0.044	1.666 ± 0.013
HIR	9.308 ± 0.276a,b	0.308 ± 0.028a,b
HIR/APRE5	6.465 ± 0.42a,b,c	1.107 ± 0.029a,b,c
HIR/APRE10	4.821 ± 0.191a,b,c,d	1.296 ± 0.056a,b,c,d
HIR/APRE20	3.264 ± 0.091a,b,c,d,e	1.463 ± 0.016a,b,c,d,e

^aP < 0.05, significantly different from Sham group.

^bP < 0.05, significantly different from Sham/aprepitant 10 mg/kg (APRE10).

^cP < 0.05, significantly different from hepatic ischemia reperfusion (HIR) group.

^dP < 0.05, significantly different from HIR/aprepitant 5 mg/kg.

^eP < 0.05, significantly different from HIR/APRE10 group.

¹Values represent the mean ± SEM (n = 5-8).

APRE5: Aprepitant 5 mg/kg; APRE10: Aprepitant 10 mg/kg; APRE20: Aprepitant 20 mg/kg; HIR: Hepatic ischemia reperfusion; MDA: Malondialdehyde; TAC: Total antioxidant capacity.